Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience

被引:18
作者
Beck, Kendall R. [1 ]
Kim, Nicole [1 ]
Khalili, Mandana [1 ,2 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,NH 3-D, San Francisco, CA 94110 USA
[2] Univ Calif San Francisco, Ctr Liver, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
HCV; Direct-acting antiviral therapy; Underserved population; Cirrhosis; Sustained virologic response; VIRUS-INFECTION; GENOTYPE;
D O I
10.1007/s10620-016-4340-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Vulnerable populations are disproportionately affected by hepatitis C virus (HCV) infection and experience high rates of health disparity. There are no data on real-world experience with highly efficacious direct-acting anti-HCV treatment in this population. We aimed to evaluate the real-world experience with sofosbuvir-based regimens among a vulnerable HCV-infected population. HCV treatment response was assessed among 204 patients who completed 12-24 weeks of sofosbuvir-based regimens (in combination with pegylated interferon and ribavirin, simeprevir, ledipasvir, or daclatasvir) at the San Francisco safety-net healthcare system liver specialty clinic between January 2014 and December 2015. Virologic response during therapy was assessed at weeks 4 and 8, end of therapy, and 12-week treatment discontinuation (SVR 12). Patient characteristics were median age 58 years, 60 % male, 42 % Caucasian (21 % black, 19 % Hispanic), 72 % had genotype 1 (23 % genotype 2 or 3), and the median baseline log(10) HCV viral load was 6.1 IU/ml and alanine transaminase 63 U/l. Cirrhosis was present in 36 % (of whom 40 % were decompensated), and 18 % were HCV treatment-experienced. Overall, SVR 12 was achieved in 97 % (99 % genotype 1, 100 % genotype 2, 84 % genotype 3). Five of six (83 %) patients who relapsed had decompensated cirrhosis, and 67 % were also non-adherent to therapy. On-treatment virologic response did not impact SVR. High rates of sustained virologic response can be achieved in safety-net HCV-infected patients. Access to DAA-based regimens is critical to addressing HCV-related health disparity in this at-risk population.
引用
收藏
页码:3602 / 3608
页数:7
相关论文
共 26 条
  • [1] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
    Afdhal, Nezam
    Zeuzem, Stefan
    Kwo, Paul
    Chojkier, Mario
    Gitlin, Norman
    Puoti, Massimo
    Romero-Gomez, Manuel
    Zarski, Jean-Pierre
    Agarwal, Kosh
    Buggisch, Peter
    Foster, Graham R.
    Braeu, Norbert
    Buti, Maria
    Jacobson, Ira M.
    Subramanian, G. Mani
    Ding, Xiao
    Mo, Hongmei
    Yang, Jenny C.
    Pang, Phillip S.
    Symonds, William T.
    McHutchison, John G.
    Muir, Andrew J.
    Mangia, Alessandra
    Marcellin, Patrick
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) : 1889 - 1898
  • [2] American Association for the Study of Liver Diseases and Infectious Diseases Society of America HCV Guidance, 2016, HCV GUID REC TEST MA
  • [3] Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans
    Backus, L. I.
    Belperio, P. S.
    Shahoumian, T. A.
    Loomis, T. P.
    Mole, L. A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) : 559 - 573
  • [4] Bindman AB, 2009, AM J MANAG CARE, V15, P747
  • [5] Health Care Coverage under the Affordable Care Act - A Progress Report
    Blumenthal, David
    Collins, Sara R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) : 275 - 281
  • [6] Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES
    Butt, Adeel A.
    Yan, Peng
    Shaikh, Obaid S.
    Chung, Raymond T.
    Sherman, Kenneth E.
    [J]. LIVER INTERNATIONAL, 2016, 36 (05) : 651 - 658
  • [7] Center for Disease Control, Viral Hepatitis
  • [8] Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1457
  • [9] Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
    Davis, Gary L.
    Alter, Miriam J.
    El-Serag, Hashem
    Poynard, Thierry
    Jennings, Linda W.
    [J]. GASTROENTEROLOGY, 2010, 138 (02) : 513 - U141
  • [10] Guerra V, 2014, CHARITY CARE ORG NAV